Drug intelligence / Profile preview

naratuximab

Development stage: Unknown
Lead developer: Debiopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Naratuximab is a humanized monoclonal antibody designed to specifically target the CD37 protein, a surface marker found on mature B cells and various B-cell malignancies. It serves as the antibody component of the antibody-drug conjugate (ADC) naratuximab emtansine (also known as Debio 1562 or IMGN529). In this ADC, naratuximab binds to CD37 on cancer cells, facilitating the internalization and targeted delivery of a cytotoxic payload, DM1, to induce cell death. The antibody component itself also contributes to therapeutic effects by inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. This targeted approach aims to enhance treatment efficacy while minimizing off-target effects.

Other names: Anti-TSPAN26/CD37 Reference Antibody (naratuximab)

Targets

CD37

Beyond the preview

Go deeper on naratuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naratuximab.

Explore the full profile